ATE526030T1 - Protein s zur verwendung als neuroprotektives mittel - Google Patents

Protein s zur verwendung als neuroprotektives mittel

Info

Publication number: ATE526030T1
Authority: AT; Austria
Prior art keywords: protein; stroke; activities; agents; oxygenation
Prior art date: 2002-09-30

Application number

AT03799306T

Other languages

English (en)

Inventor

Berislav Zlokovic

John Griffin

Original Assignee

Zz Biotech L L C

Univ Rochester

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-30

Filing date

2003-09-30

Publication date

2011-10-15

2003-09-30 Application filed by Zz Biotech L L C, Univ Rochester, Scripps Research Inst filed Critical Zz Biotech L L C

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE526030T1 publication Critical patent/ATE526030T1/de

Links

239000004090 neuroprotective agent Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
229940096437 Protein S Drugs 0.000 abstract 5
102000029301 Protein S Human genes 0.000 abstract 4
108010066124 Protein S Proteins 0.000 abstract 4
206010021143 Hypoxia Diseases 0.000 abstract 2
208000006011 Stroke Diseases 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
230000006378 damage Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
208000014674 injury Diseases 0.000 abstract 2
238000006213 oxygenation reaction Methods 0.000 abstract 2
206010048962 Brain oedema Diseases 0.000 abstract 1
102000009123 Fibrin Human genes 0.000 abstract 1
108010073385 Fibrin Proteins 0.000 abstract 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
208000032382 Ischaemic stroke Diseases 0.000 abstract 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002785 anti-thrombosis Effects 0.000 abstract 1
239000003146 anticoagulant agent Substances 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
208000006752 brain edema Diseases 0.000 abstract 1
201000008247 brain infarction Diseases 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
206010008118 cerebral infarction Diseases 0.000 abstract 1
210000003618 cortical neuron Anatomy 0.000 abstract 1
230000008021 deposition Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229950003499 fibrin Drugs 0.000 abstract 1
230000007954 hypoxia Effects 0.000 abstract 1
230000001146 hypoxic effect Effects 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000007658 neurological function Effects 0.000 abstract 1
210000000440 neutrophil Anatomy 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000010410 reperfusion Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT03799306T 2002-09-30 2003-09-30 Protein s zur verwendung als neuroprotektives mittel ATE526030T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41433302P	2002-09-30	2002-09-30
PCT/US2003/030638 WO2004030619A2 (en)	2002-09-30	2003-09-30	Protein s protects the nervous system from injury

Publications (1)

Publication Number	Publication Date
ATE526030T1 true ATE526030T1 (de)	2011-10-15

Family

ID=32069725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03799306T ATE526030T1 (de)	2002-09-30	2003-09-30	Protein s zur verwendung als neuroprotektives mittel

Country Status (6)

Country	Link
US (1)	US7968515B2 (de)
EP (1)	EP1572134B1 (de)
AT (1)	ATE526030T1 (de)
AU (1)	AU2003277034A1 (de)
CA (1)	CA2499458C (de)
WO (1)	WO2004030619A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1572134B1 (de)	2002-09-30	2011-09-28	Zz Biotech L.L.C.	Protein s zur verwendung als neuroprotektives mittel
JP2009504636A (ja) *	2005-08-11	2009-02-05	メディジーンズカンパニーリミテッド	血漿または血清を含む神経損傷治療用の医薬組成物
CN104122396A (zh) *	2013-04-23	2014-10-29	中国科学院上海生命科学研究院	维生素k依赖性蛋白s作为糖尿病标志物的应用
DE102013209820B4 (de)	2013-05-27	2025-01-30	Hamm Ag	Selbstfahrende Straßenbaumaschine, insbesondere Straßenwalze, sowie Verfahren zum Fahren und Lenken einer Straßenbaumaschine
US11007254B2 (en)	2016-10-17	2021-05-18	Musc Foundation For Research Development	Compositions and methods for treating central nervous system injury

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5534617A (en)	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5254532A (en) *	1989-06-26	1993-10-19	Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte	Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
US5321123A (en) *	1991-07-02	1994-06-14	The Scripps Research Institute	Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
US5405946A (en) *	1992-12-02	1995-04-11	The Scripps Research Institute	Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
EP0706564A1 (de) *	1993-06-30	1996-04-17	Rijksuniversiteit Leiden	Protein s deletionsvarianten mit mangel an bindungsaktivitaet fuer c4bp, aber mit apc- cofaktor- aktivitaet, zusammensetzungen und therapeutische verfahren
DE4418635C2 (de) *	1994-05-27	1997-07-24	Immuno Ag	Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
DE19531637A1 (de) *	1995-08-28	1997-03-06	Immuno Ag	Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
WO1997016169A1 (en) *	1995-11-01	1997-05-09	Chiron Corporation	Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6379975B1 (en) *	1996-11-27	2002-04-30	T.A.C. Thrombosis And Coagulation Aktiebolag	Methods and reagents for determining protein S
ATE504310T1 (de) *	2000-02-04	2011-04-15	Scripps Research Inst	Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
US20030165485A1 (en) *	2001-11-09	2003-09-04	Goran Bertilsson	Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
EP1572134B1 (de)	2002-09-30	2011-09-28	Zz Biotech L.L.C.	Protein s zur verwendung als neuroprotektives mittel
WO2004056309A2 (en)	2002-12-05	2004-07-08	Socratech L.L.C.	Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) *	2003-01-24	2007-06-21	Zlokovic Berislav V	Neuroprotective activity of activated protein c independent of its anticoagulant activity

2003
- 2003-09-30 EP EP03799306A patent/EP1572134B1/de not_active Expired - Lifetime
- 2003-09-30 AU AU2003277034A patent/AU2003277034A1/en not_active Abandoned
- 2003-09-30 CA CA2499458A patent/CA2499458C/en not_active Expired - Fee Related
- 2003-09-30 US US10/529,748 patent/US7968515B2/en not_active Expired - Fee Related
- 2003-09-30 AT AT03799306T patent/ATE526030T1/de not_active IP Right Cessation
- 2003-09-30 WO PCT/US2003/030638 patent/WO2004030619A2/en not_active Ceased

Also Published As

Publication number	Publication date
US7968515B2 (en)	2011-06-28
EP1572134A2 (de)	2005-09-14
US20060052281A1 (en)	2006-03-09
WO2004030619A2 (en)	2004-04-15
AU2003277034A8 (en)	2004-04-23
WO2004030619A3 (en)	2005-06-02
EP1572134A4 (de)	2008-07-09
EP1572134B1 (de)	2011-09-28
CA2499458C (en)	2013-11-12
WO2004030619A8 (en)	2004-11-25
CA2499458A1 (en)	2004-04-15
AU2003277034A1 (en)	2004-04-23

Similar Documents

Publication	Publication Date	Title
ATE490786T1 (de)	2010-12-15	Behandlung von verletzungen des zentralen nervensystems
ATE381935T1 (de)	2008-01-15	Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
WO2000027422A3 (en)	2000-11-09	Methods and compositions for treating or preventing peripheral neuropathies
BR0313239A (pt)	2005-06-14	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
DE60216139D1 (de)	2006-12-28	Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
DE60237158D1 (de)	2010-09-09	Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
ATE218360T1 (de)	2002-06-15	Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
NO20004800D0 (no)	2000-09-26	Antagonister for behandling av CD11/CD18 adhesjonsreseptormedierte forstyrrelser
ATE501732T1 (de)	2011-04-15	Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
WO2004026246A3 (en)	2004-07-01	Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
BRPI0407662B8 (pt)	2021-05-25	derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
WO2002036829A3 (en)	2003-03-13	Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
WO2004096216A3 (en)	2005-04-14	Use of a topical medicament comprising riluzole
DE69433309D1 (de)	2003-12-18	Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
ATE504310T1 (de)	2011-04-15	Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
DE60324535D1 (de)	2008-12-18	Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen
BR0201862A (pt)	2003-03-25	Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
ATE526030T1 (de)	2011-10-15	Protein s zur verwendung als neuroprotektives mittel
EA200501479A1 (ru)	2006-02-24	Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
DK1032556T3 (da)	2008-03-25	Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
EP1401496A4 (de)	2005-08-31	Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE59710517D1 (de)	2003-09-04	Adamantanaminenderivate zur bekämpfung von viren der familie bornaviridae
CA2534303A1 (en)	2005-02-24	Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
ATE435649T1 (de)	2009-07-15	4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3- carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties